Accustem Sciences Inc. (ACUT) intrinsic value & 10-year financials
Accustem Sciences Inc. (ACUT) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.15
- Market cap
- $2.2M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -248.9%
- Free cash flow (FY2025)
- —
ACUT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$1.8M | -$0.12 | — | — | 52.3% |
| FY2024 | — | -$1.5M | -$0.13 | — | — | 55.5% |
| FY2023 | — | -$2.1M | -$0.18 | — | — | 182.2% |
| FY2022 | — | -$3.7M | -$0.34 | -$1.8M | — | -1466.0% |
| FY2021 | — | -$670.6K | — | — | — | -68.4% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Accustem Sciences Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Accustem Sciences Inc. has historically struggled to out-earn its cost of capital, averaging just 5.3% ROIC.
Accustem Sciences Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Accustem Sciences Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.